340B Drug Pricing Program
AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency (PHE).
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY
Government’s Opposition to Motion to Intervene - AstraZeneca v. Cochran (March 12, 2021)
AstraZeneca’s Opposition to Motion to Intervene (March 12, 2021) Insert
Associations’ Reply in Support of Motion to Intervene - AstraZeneca v. Cochran (March 19, 2021)
American Hospital Association, 340B Health, America’s Essential Hospitals, Association of American Medical Colleges, National Association of Children’s Hospitals d/b/a Children’s Hospital Association, and American Society of HealthSystem Pharmacists (collectively the “Proposed Intervenors”) move…
Response to Motion to Intervene - SANOFI-AVENTIS vs HHS (March 22, 2021)
UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION
ELI LILLY AND COMPANY,
Lilly Corporate Center
893 Delaware Street
Indianapolis, IN 46225, et al.,
IN THE UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION